Repare Therapeutics Inc.
RPTX
$1.59
$0.042.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 250.00K | -- | 0.00 | -- | 1.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.00K | -- | 0.00 | -- | 1.07M |
| Cost of Revenue | 14.28M | 20.27M | -78.07M | 28.40M | 30.08M |
| Gross Profit | -14.03M | -20.27M | 78.07M | -28.40M | -29.00M |
| SG&A Expenses | 6.03M | 7.65M | 8.84M | 6.44M | 8.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.31M | 27.92M | 30.80M | 34.85M | 38.39M |
| Operating Income | -20.06M | -27.92M | -30.80M | -34.85M | -37.32M |
| Income Before Tax | -16.50M | -29.67M | -28.67M | -33.92M | -34.45M |
| Income Tax Expenses | 248.00K | 370.00K | 0.00 | 485.00K | 326.00K |
| Earnings from Continuing Operations | -16.74M | -30.04M | -28.67M | -34.41M | -34.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.74M | -30.04M | -28.67M | -34.41M | -34.77M |
| EBIT | -20.06M | -27.92M | -30.80M | -34.85M | -37.32M |
| EBITDA | -19.03M | -26.74M | -30.34M | -34.37M | -36.83M |
| EPS Basic | -0.39 | -0.71 | -0.67 | -0.81 | -0.82 |
| Normalized Basic EPS | -0.27 | -0.39 | -0.42 | -0.48 | -0.51 |
| EPS Diluted | -0.39 | -0.71 | -0.67 | -0.81 | -0.82 |
| Normalized Diluted EPS | -0.27 | -0.39 | -0.42 | -0.48 | -0.51 |
| Average Basic Shares Outstanding | 42.92M | 42.59M | 42.51M | 42.45M | 42.45M |
| Average Diluted Shares Outstanding | 42.92M | 42.59M | 42.51M | 42.45M | 42.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |